A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)

Inclusion Criteria:

   - Women aged 18 years or older of any race with an American Society of Anesthesiologists
   (ASA) physical status of I to III who are scheduled to undergo elective open abdominal
   surgery under general anesthesia.

   - Women whose postoperative hospitalization is expected to last at least 24 hours

   - Women expected to require postoperative intravenous opioid PCA.

   - Women whose surgery is expected to require at least 1 hour, but not more than 4 hours,
   of general anesthesia using the regimen defined in this protocol.

   - Women of childbearing potential who have a negative pregnancy test or women who have
   been surgically sterilized or are postmenopausal.

Exclusion Criteria:

   - Women with clinically significant or unstable cardiac, respiratory, hepatic, renal, or
   other major organ system disease.

   - Women with a known hypersensitivity to ondansetron (or any other 5-HT3 antagonist), to
   any agent that is part of the anesthesia regimen, or to other medications to be
   administered under this protocol.

   - Women who are scheduled to undergo certain types of surgery.

   - Women who are breastfeeding.

   - Women who have retching/vomiting or moderate or severe nausea in the 24 hours prior to
   surgery or suffer from chronic nausea and/or vomiting.

   - Women with a body mass index (BMI) >40.

   - Women who have participated in a clinical trial of an investigational drug within 30
   days prior to drug administration.